Dr. Krishna Allamneni Concarlo Therapeutics, USA

Dr. Krishna Allamneni is a seasoned biopharmaceutical executive with a 20+ year track record in translating benefit-risk for global regulatory authorities across diverse therapeutic areas. She led the early development of seven successful marketed products and managed 25+ IND programs. Currently, Dr. Allamneni serves as the Executive Vice President and... read moreChief Development Officer at Concarlo Therapeutics, Inc., an oncology seed-stage start-up company focusing on a p27 inhibitor. In this pivotal role, she leads the strategic direction of the p27 targeting pipeline, steering its progression from preclinical to clinical phases across diverse portfolio strategies. Her comprehensive operational oversight encompasses key functions, including Preclinical and Nonclinical Translational Research and Development, CMC (Chemistry, Manufacturing, and Controls) & Preformulation, Pipeline and Portfolio Management, as well as Clinical and Regulatory Strategy, and Scientific and Medical Affairs.Previously, she was Vice President and Head of Development Sciences at Turning Point Therapeutics, Inc. (now a Bristol Myers Squibb company) and served in various leadership roles at Jazz Pharmaceuticals, NGM Biopharmaceuticals, and Genentech after serving as a toxicology subject matter expert at companies such as Celera Genomics. She has also contributed to the American College of Toxicology as its board member. Krishna's leadership ensures expedited and cost-effective global early development regulatory strategies, making her a trusted figure in the clinical and investment communities. Krishna is a board-certified toxicologist, with a Postdoctoral Training in Pathology and Developmental Lung Biology from Harvard Medical School, an MS/PhD in Pharmacology/Toxicology from University of California, Davis, and a Bachelor of Veterinary Science and Animal Husbandry (Doctor of Veterinary Medicine equivalent).